

Plenary Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10213	Junya Mita	FSP1 Drives Ferroptosis Resistance and an Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma	Oral	Plenary Session	Friday September 18, 2026	13:40-14:10	10min
10058	Yuta Myojin	Childhood Obesity Promotes Liver Cancer Susceptibility Later in Life in Mouse Models	Oral	Plenary Session	Friday September 18, 2026	13:40-14:10	10min
10124	Keisuke Okura	Intermediate- to High-Risk Subgroups of Hepatocellular Carcinoma Characterized by Recurrence-Survival Correlation after Hepatectomy	Oral	Plenary Session	Friday September 18, 2026	13:40-14:10	10min

Free Papers Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10198	Haruki Ichino	Nucleos(t)ide Analogs for Hepatitis B Virus Infection Differentially Regulate the Growth Factor Signaling in Hepatocytes	Oral	HBV: From Basics to Risk Stratification (Tentative)	Friday September 18, 2026	18:05-18:55	7min
10094	Kazuhisa Murai	Netrin-1 is a Novel Host Factor That Dually Inhibits HBV Entry	Oral	HBV: From Basics to Risk Stratification (Tentative)	Friday September 18, 2026	18:05-18:55	7min
10362	Zhaoyu Yan	RBP3 is a Novel Host Regulator of HBV Protein Expression and Viral Replication	Oral	HBV: From Basics to Risk Stratification (Tentative)	Friday September 18, 2026	18:05-18:55	7min
10096	Xiaolei Jin	Multi-Locus HLA Evolutionary Divergence and Spontaneous Hbsag Seroclearance in Chronic Hepatitis B: a Longitudinal Taiwan Biobank Study	Oral	HBV: From Basics to Risk Stratification (Tentative)	Friday September 18, 2026	18:05-18:55	7min
10169	Sang Gyune Kim	Fibrosis Burden Outperforms HBV DNA in Predicting Hepatocellular Carcinoma and Liver-Related Outcomes in Patients with Indeterminate-Phase Chronic Hepatitis B	Oral	HBV: From Basics to Risk Stratification (Tentative)	Friday September 18, 2026	18:05-18:55	7min
10344	Rui Huang	iREAL-B as a Simple Risk Score for Predicting Hepatocellular Carcinoma in Untreated Indeterminate Chronic Hepatitis B Patients	Oral	HBV: From Basics to Risk Stratification (Tentative)	Friday September 18, 2026	18:05-18:55	7min

Free Papers Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10057	Sadatsugu Sakane	Serum Fibulin-3 Predicts Hepatocellular Carcinoma Development in Patients with MASLD and Post-DAA Chronic Hepatitis C	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min
10355	Seong Hee Kang	Protective Effect of SGLT2 Inhibitors Against Hepatocellular Carcinoma and Cirrhosis in Patients with Diabetes and Chronic Hepatitis B/C	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min
10123	Takuma Kaneko	AI Based Local Tumor Progression Prediction Following Hepatocellular Carcinoma Ablation	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min
10275	Wenzhen Ding	A Multimodal Highly Conformal Ablation Planning System for Hepatocellular Carcinoma: a Multicenter Retrospective and Prospective Study	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min
10003	Fujimasa Tada	Clinical Significance and Determinants of Hemorrhagic Events in Unresectable Hepatocellular Carcinoma under Atezolizumab Plus Bevacizumab Therapy	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min
10174	Joji Tani	Real-World Outcomes and Treatment Strategy of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: a Multicenter Study of 448 Patients	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min
10085	Yosuke Murata	Molecular Analysis of Circulating Tumor Cells as a Translational Biomarker for Systemic Therapy in Patients with Hepatocellular Carcinoma	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min
10354	Seong Hee Kang	Predictors of Hepatocellular Carcinoma in Cirrhotic Patients: the Role of Glucose Tolerance and Fasting Glycemia	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min
10006	Ying Nan Tsa	Comparative Effectiveness and Safety of Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab as First-Line Systemic Therapy for Hepatocellular Carcinoma: a Real-World Study	Oral	Liver Cancer: Clinical Practice and Systemic Therapy (Tentative)	Saturday September 19, 2026	9:10-10:20	7min

Free Papers Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10092	Yu Saito	Beyond BR1/BR2: Defining Surgical Indications for Borderline Resectable Hepatocellular Carcinoma Using Tumour Burden and Vascular Invasion	Oral	Surgery, Biliary Diseases, and Other Topics (Tentative)	Saturday September 19, 2026	14:40-15:10	8min
10187	Sota Nakamura	Metabolic Refinement of Oncological Resectability Classification Using FDG-PET-Derived Suvmax in Resected Hepatocellular Carcinoma	Oral	Surgery, Biliary Diseases, and Other Topics (Tentative)	Saturday September 19, 2026	14:40-15:10	8min
10239	Song Huy Nguyen Dinh	Long-Term Outcomes and Prognostic Factors Following Liver Resection for Hepatocellular Carcinoma	Oral	Surgery, Biliary Diseases, and Other Topics (Tentative)	Saturday September 19, 2026	14:40-15:10	8min

Free Papers Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10251	Xian-Yang Qin	MYCN Defines Stress-Adaptive Cell States in Hepatocellular Carcinoma	Oral	HCC: Basic & Translationa (Tentative)	Saturday September 19, 2026	15:05-15:35	7min
10036	Chaiyaboot Ariyachet	ZNF469 Coordinates a Metabolic Program for Collagen Synthesis by Regulating Amino Acid Transport and Biosynthetic Enzymes	Oral	HCC: Basic & Translationa (Tentative)	Saturday September 19, 2026	15:05-15:35	7min
10205	T Ishikawa	Lactylation Regulates Ferroptosis through METTL3 in Hepatocellular Carcinoma	Oral	HCC: Basic & Translationa (Tentative)	Saturday September 19, 2026	15:05-15:35	7min
10230	Yosuke Fujii	Hepatocyte-Specific <i>Arid1a</i> Loss Favors Hepatocarcinogenesis under Chronic Liver Injury	Oral	HCC: Basic & Translationa (Tentative)	Saturday September 19, 2026	15:05-15:35	7min

Free Papers Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10076	Eun Seok Kang	Development and Multicentre Validation of a Routine-Laboratory Model for Fibroscan-Defined Steatosis and Fibrosis Staging	Oral	MASLD/ALD 1	Saturday September 19, 2026	15:45-16:30	7min
10340	Mohammad Ahmadullah Khan	FIB-4 False Negatives in MASLD: Clinical Phenotypes and an Augmented Triage Mode	Oral	MASLD/ALD 1	Saturday September 19, 2026	15:45-16:30	7min
10079	Naing Naing Mon	A Conjugated Bile Acid-Extracellular Matrix Axis Characterises Fibrosis-Dominant MASLD and Steatosis-Fibrosis Discordance	Oral	MASLD/ALD 1	Saturday September 19, 2026	15:45-16:30	7min
10102	Juhun Choi	Association between Circadian Rhythm-Disturbing Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease among Korean Adults	Oral	MASLD/ALD 1	Saturday September 19, 2026	15:45-16:30	7min
10155	Sae Kyung Joo	Sex Differences in Fatty Liver Prevalence at Comparable Body Fat Levels: the Contribution of Central Adiposity	Oral	MASLD/ALD 1	Saturday September 19, 2026	15:45-16:30	7min
10249	Cheng-Han Ng	Sarcopenic Obesity Is Associated with MASLD and All-Cause Mortality among Adults with Obesity	Oral	MASLD/ALD 1	Saturday September 19, 2026	15:45-16:30	7min

Free Papers Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10178	Yoshihiro Kamada	Delphi-Based Non-Invasive Algorithms for Liver-Directed Semaglutide Therapy in MASLD	Oral	MASLD/ALD 2	Saturday September 19, 2026	16:35-17:20	7min
10306	Yuji Ikeda	Identifying Significant Fibrosis in Health-Check MASLD: Added Value of MAF-5 in Normal ALT and Non-Obese Individuals	Oral	MASLD/ALD 2	Saturday September 19, 2026	16:35-17:20	7min
10270	Chikako Sakai	Real-World Efficacy and Safety of Tirzepatide in Patients with T2DM and MASLD: a Prospective Cohort with Multicenter Retrospective Validation	Oral	MASLD/ALD 2	Saturday September 19, 2026	16:35-17:20	7min
10357	Cosmas Rinaldi Adithya Lesmana	The Hidden Portal Pressure Burden in MASLD: EUS-PPG Reveals a Non-Invasive Marker and Portal Pressure Mismatch in a Prospective Pilot Cohort	Oral	MASLD/ALD 2	Saturday September 19, 2026	16:35-17:20	7min
10132	Hideki Fujii	Role of Diabetes Mellitus and Platelet Count in Hepatocellular Carcinoma Development in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	Oral	MASLD/ALD 2	Saturday September 19, 2026	16:35-17:20	7min
10005	Yukihiro Watanabe	Burnt-out MASLD Predicts Outcomes after Curative Resection for Hepatocellular Carcinoma	Oral	MASLD/ALD 2	Saturday September 19, 2026	16:35-17:20	7min

Free Papers Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10105	Haeun Ryu	Association between Magnetic Resonance Imaging-Assessed Myosteatosis and the Risk of Major Adverse Liver Outcomes	Oral	Theme: Cirrhosis Risk and Complications (Tentative)	Saturday September 19, 2026	16:50-17:20	8min
10268	Keiichi Katayama	Impact of Acid-Suppressing Therapy on Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis: a Prospective Cohort Study	Oral	Theme: Cirrhosis Risk and Complications (Tentative)	Saturday September 19, 2026	16:50-17:20	8min
10307	Zento Yamada	Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients with Cirrhosis and Hepatic Edema	Oral	Theme: Cirrhosis Risk and Complications (Tentative)	Saturday September 19, 2026	16:50-17:20	8min

Free Papers Session

No	Name	Title of Abstract	Style	Session Theme	Session Date	Session Time (Tentative)	Presentation Time
10045	Shoma Yoneda	Diagnostic Performance of Serum Methylated Somatostatin Liquid Biopsy for Hepatocellular Carcinoma: Comparison with Methylated <I>HOXA1</I> and <I>SEPT9</I>	Oral	Liver Cancer Risk, Surveillance, and Early Diagnosis (Tentative)	Saturday September 19, 2026	16:50-17:20	7min
10108	Jia-Ling Wu	Risks of Hepatocellular Carcinoma and Cause-Specific Mortality in Chronic Hepatitis B with Versus without Tyg-WC-Defined MASLD Proxy: a Nationwide Cohort Study	Oral	Liver Cancer Risk, Surveillance, and Early Diagnosis (Tentative)	Saturday September 19, 2026	16:50-17:20	7min
10121	Atsushi Yukimoto	Hepatocellular Carcinoma Following SVR in Patients with HCV Associated Cirrhosis and Stratification of Risk Factors: a Multicenter Study	Oral	Liver Cancer Risk, Surveillance, and Early Diagnosis (Tentative)	Saturday September 19, 2026	16:50-17:20	7min
10197	Katsuya Nagaoka	Bridging the Surveillance Gap in Steatotic and Alcohol-Related Hepatocellular Carcinoma	Oral	Liver Cancer Risk, Surveillance, and Early Diagnosis (Tentative)	Saturday September 19, 2026	16:50-17:20	7min

*The program is subject to change.